-
-
Editor's Choice -
Pharma & Human Health -
Pharma & Human Health -
Pharma & Human Health
Editor’s Choice
Editor's Choice
Microbiotica Announces Impressive Results in its Phase 1b Trial of MB310 in Ulcerative Colitis
Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products (LBPs), announces positive results in its Phase 1b First-in-Human trial, COMPOSER-1, of MB310 in ulcerative colitis (UC) patients. […]
Editor's Choice
Immunity as a Lifestyle Priority
Immune health has evolved from a seasonal concern to an essential part of everyday well-being. Consumers are adopting proactive strategies that combine healthy lifestyle habits with advanced biotic solutions, driving innovation across the supplement industry. […]
Editor's Choice
Siolta Therapeutics Reports Positive Phase 2 Results from the ADORED Study
Siolta Therapeutics, a clinical-stage biotech company developing first-in-class live biotherapeutic products (LBPs), today announced positive top-line results from the Phase 2 ADORED study (Allergic Disease Onset pREvention stuDy) of STMC-103H, its lead investigational oral microbial […]
In Case you Missed it:
Pharma & Human Health
UC San Diego researchers develop new tool to predict how bacteria influence health
University of California San Diego researchers have developed an innovative new tool called coralME to better understand how microbes interact with each other and their environment to influence health. The tool rapidly creates detailed genome-scale […]
Pharma & Human Health
Traces of bacteria inside brain tumors may affect tumor behavior
Researchers at The University of Texas MD Anderson Cancer Center have uncovered unexpected traces of bacteria within brain tumors. This discovery offers new insights into the environment in which brain tumors grow and sets the […]
Pharma & Human Health
Whitepaper: Oral Drug Delivery of Live Biotherapeutics: From Development to Clinical Trial with EUDRACAP® Select
Delivering live biotherapeutics orally remains one of the challenges in microbiome therapy. In this white paper, Evonik presents a real-world case study of how EUDRACAP® Select—a ready-to-fill enteric capsule—enabled the safe and targeted delivery of […]
Editor's Choice
Siolta Therapeutics Reports Positive Phase 2 Results from the ADORED Study
Siolta Therapeutics, a clinical-stage biotech company developing first-in-class live biotherapeutic products (LBPs), today announced positive top-line results from the Phase 2 ADORED study (Allergic Disease Onset pREvention stuDy) of STMC-103H, its lead investigational oral microbial […]
Editor's Choice
The OMNIgene™•VAGINAL device – Optimized solutions for vaginal microbiome studies
The women’s health gap refers to disparities in health outcomes and the limited research into conditions that exclusively affect women or affect them differently from men. This gap stems from the historic exclusion of females […]
Pharma & Human Health
Ferring Presents New Data Analyses for REBYOTA®
Ferring Pharmaceuticals shared an oral presentation last month detailing microbiome restoration from the Phase 3b CDI-SCOPE study among patients with recurrent C. difficile (C. diff) infection (CDI) who received REBYOTA® (fecal microbiota, live – jslm). This research was […]
Finance
Ascribe Bio Closes $12 Million Series A Financing to Advance Next-Generation Natural Crop Protection
Ascribe Bio, an innovator in natural crop protection, announced the closing of an oversubscribed $12 million Series A financing round, co-led by Corteva, through its Corteva Catalyst platform, and Acre Venture Partners. The financing also included participation […]
Finance
Seres Therapeutics Receives Award of up to $3.6M from Carb-X to Develop Liquid Formulation of Ser-155
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, announced that CARB-X, a global non-profit partnership accelerating antibacterial products to address drug-resistant bacteria, will provide up to $3.6 million in additional non-dilutive funding to […]
